Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316670 | 0.99 | CNR2 (0.56) | CNR2CNR1MAPK8ALDH1A1 | |
| SCHEMBL5244117 | 0.84 | CNR2 (0.40) | CNR2CNR1MAPK8ALDH1A1UGCG | |
| SCHEMBL315909 | 0.83 | CNR2 (0.51) | CNR2CNR1MAPK8ALDH1A1 | |
| SCHEMBL316096 | 0.82 | CNR2 (0.55) | CNR2CNR1MAPK8ALDH1A1UGCG | |
| SCHEMBL316570 | 0.78 | ALDH1A1 (0.56) | CNR2CNR1ALDH1A1 | |
| SCHEMBL5244360 | 0.78 | CNR2 (0.35) | CNR2CNR1MAPK8ALDH1A1UGCG | |
| SCHEMBL316105 | 0.78 | L3MBTL1 (0.51) | CNR2CNR1MAPK8ALDH1A1UGCG | |
| SCHEMBL316300 | 0.77 | CNR2 (0.53) | CNR2CNR1MAPK8ALDH1A1UGCG | |
| SCHEMBL5242859 | 0.77 | CNR2 (0.43) | CNR2CNR1MAPK8ALDH1A1UGCG | |
| SCHEMBL316471 | 0.77 | CNR2 (0.55) | CNR2CNR1MAPK8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745009-B1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-11-14 | — | — | EP | claimed |
| US-8093272-B2 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| EP-1745009-B1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-11-14 | — | — | EP | disclosed |
| US-8093272-B2 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | DDC, DPYD, PKD1 | CNR2 1164/4885CNR1 920/4885MAPK8 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.